PublicationsAntibodyAAV SubtypeApplications

Tseng, Y.-S. et al. Adeno-Associated Virus Serotype 1 (AAV1)-and AAV5-Antibody Complex Structures Reveal Evolutionary Commonalities in Parvovirus Antigenic Reactivity. J. Virol. 89, 1794–1808 (2015).

610150, 651150, 615150, 610148, 651148, 652148, 615148, 610149, 651149AAV1, 5neutralization assay, epitope mapping
Dutheil, N. et al. Adeno-Associated Virus Rep Represses the Human Integration Site Promoter by Two Pathways That Are Similar to Those Required for the Regulation of the Viral p5 Promoter. J. Virol. 88, 8227–8241 (2014).61069AAV2WB

Mietzsch, M. et al. OneBac: Platform for Scalable and High-Titer Production of Adeno-Associated Virus Serotype 1–12 Vectors for Gene Therapy. Hum. Gene Ther. 25, 212–222 (2014).

610150, 651150, 61055, 65155, 65255, 610147, 651147, 652147, 610148, 651148, 652148, 61056, 65156, 61058, 65158, 61084, 61069, 65169, 651159, 651162, 651160, 652160, 610160AAV1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12WB, dot blot

Jin, L.-F. et al. Ultrasound Targeted Microbubble Destruction Stimulates Cellular Endocytosis in Facilitation of Adeno-Associated Virus Delivery. Int. J. Mol. Sci 14, 9737–9750 (2013).

61055, 61058AAV2WB, ICC-IF

Gurda, B. L. et al. Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8. J. Virol. 86, 7739–7751 (2012).

651160, 652160, 610160AAV8ELISA, ICC-IF, dot blot, neutralization assay, epitope mapping

Raupp, C. et al. The Threefold Protrusions of Adeno-Associated Virus Type 8 Are Involved in Cell Surface Targeting as Well as Postattachment Processing. J. Virol. 86, 9396–9408 (2012).

652160, 610160, 651160AAV8neutralization assay

Naumer, M. et al. Properties of the Adeno-Associated Virus Assembly-Activating Protein. J. Virol. 86, 13038–13048 (2012).

61055, 65155, 61555, 65255, 61058, 65158, 61084AAV2WB, ELISA, dot blot

Sonntag, F. et al. The Assembly-Activating Protein Promotes Capsid Assembly of Different Adeno-Associated Virus Serotypes. J. Virol. 85, 12686–12697 (2011).

610150, 651150, 61055, 65155, 65255, 610137, 61058, 65158, 61084, 651159, 651162, 651160, 652160, 610160AAV1, 2, 3, 4, 5, 6, 8, 9WB, ELISA, ICC-IF, dot blot

Gonçalves, M. A. F. V et al. Targeted Chromosomal Insertion of Large DNA into the Human Genome by a Fiber-Modified High-Capacity Adenovirus-Based Vector System. PLoS One 3, (2008).

61069AAV2WB, ICC-IF

Fragkos, M., Breuleux, M., Clément, N. & Beard, P. Recombinant Adeno-Associated Viral Vectors Are Deficient in Provoking a DNA Damage Response. J. Virol. 82, 7379–7387 (2008).

61058AAV2WB

Kuck, D., Kern, A. & Kleinschmidt, J. A. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140, 17–24 (2007).

610150, 651150, 615150, 610147, 651147, 615147, 652147, 610148, 651148, 652148, 615148, 610149, 651149, 61058, 65158, 61084AAV1, 2, 3, 4, 5, 6, 8, 9WB, ELISA, ICC-IF, IP, dot blot

Kuck, D. et al. Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1. J. Virol. 80, 2621–2630 (2006).

61084AAV5WB

Grimm, D., Kay, M. A. & Kleinschmidt, J. A. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7, 839–850 (2003).

61056, 65156, 61058, 65158, 61084, 61069AAV2WB

Yan, Z. et al. Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors. J. Virol. 76, 2043–2053 (2002).

61058, 65158AAV2, 5WB

Zhang, H.-G. et al. Addition of Six-His-Tagged Peptide to the C Terminus of Adeno-Associated Virus VP3 Does Not Affect Viral Tropism or Production. J. Virol. 76, 12023–12031 (2002).

61058, 65158AAV2WB

Moskalenko, M. et al. Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure. Jounal Virol. 74, 1761–1766 (2000).

61055, 65155, 65255AAV2neutralization assay

Wobus, C. E. et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281–93 (2000).

61055, 65155, 65255, 61056, 65156, 61057, 65157, 61058, 65158AAV2, 3neutralization assay, epitope mapping

Grimm, D. et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322–30 (1999).

61055, 65155, 61555, 65255AAV2ELISA
Bartlett, J. S., Kleinschmidt, J., Boucher, R. C. & Samulski, R. J. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab’gamma)2 antibody. Nat. Biotechnol. 17, 181–6 (1999).61055, 65155, 65255AAV2 

Wistuba, A. et al. Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly. J. Virol. 71, 1341–1352 (1997).

61055, 65155, 65255, 61056, 65156, 61057, 65157, 61058, 65158, 61073AAV2WB, ICC-IF, IP

Wistuba, A., Weger, S., Kern, A., Rgen, J. & Kleinschmidt, A. Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins. J. Virol. 69, 5311–5319 (1995).

61055, 65155, 65255, 61057, 65157, 61058, 65158, 61069, 65169, 61073AAV2WB, IP